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1682-606X/Copyright ª 2015, TaiwanAbstract Background: The increasing lifespan of the aging population has resulted in an
increased number of elderly patients with esophageal cancer.
Purpose: This study was conducted to determine the effects of age on outcomes following sur-
gery in elderly patients with esophageal cancer.
Methods: Patients with esophageal cancer who received curative esophagectomy between
January 2001 and December 2012 were enrolled in this study. The patients were divided into
two groups according to their age at diagnosis: Group 1 comprised patients aged 70 years and
Group 2 comprised patients aged <70 years. Perioperative variables, the length of hospital
stay, rates of surgery-related morbidity and mortality, and survival outcomes were analyzed
and compared between the two groups.
Results: The study comprised 185 patients, with 39 patients in Group 1 and 146 patients in
Group 2. Perioperative variables, namely pulmonary function, chemoradiotherapy, length of
intensive care unit stay (4.5 days vs. 3.1 days), and hospital stay (30.2 days vs. 21.6 days), were
significantly different between the two groups. The patients in Group 1 showed higher mortal-
ity (7.7% vs. 3.4%) and morbidity (46.1% vs. 29.5%) compared with those in Group 2, with no
statistical significance. Cardiopulmonary-related complications (30.8%) following esophagect-
omy were most frequently observed in elderly patients. With less intensive chemotherapy and/
or radiotherapy, the overall survival of the patients in Group 1 was prolonged compared with
that of the patients in Group 2 (15.8 months vs. 13.7 months, p Z 0.44). Esophagectomy fol-
lowed by chemoradiotherapy did not yield more positive outcomes than those of esophagect-
omy alone in patients in Group 1.ave no conflicts of interest.
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122 H.-C. Liu et al.Conclusion: Esophagectomy in elderly patients with esophageal cancer can yield an acceptable
outcome and fewer complications than esophagectomy in younger patients. Although reserved
physiological functions are typically limited in elderly patients relative to younger patients,
elderly patients with resectable esophageal cancer should not be denied esophagectomy.
Copyright ª 2015, Taiwan Surgical Association. Published by Elsevier Taiwan LLC. All rights
reserved.1. Introduction
Esophageal cancer is a highly fatal disease.1,2 Esoph-
agectomy is commonly accepted as a local curative treat-
ment for esophageal cancer and offers an opportunity for
long-term survival.1,3,4 Because of the globally increasing
life expectancy and size of the aged population,5e9 a
growing number of elderly patients are becoming potential
candidates for esophagectomy for esophageal cancer.7,8
However, esophagectomy, being a major operative sur-
gery, has previously shown high mortality and poor long-
term survival in elderly patients.10e12 Despite advanced
surgical technologies and perioperative care techniques,
the adequacy of esophagectomy in elderly patients with
esophageal cancer remains controversial.5,10 Data on the
effects of surgery and the survival outcome following
esophagectomy in elderly patients remain scant.5,8,9 The
short-term surgical risk and potential loss in quality of life
must be analyzed against the long-term benefit of the
surgery.
No standard cutoff age for identifying patients as elderly
in relation to esophagectomy has been defined. Along with
a gradual decline in physiological function and functional
reserve, aging slows the process of recovery from major
stress conditions such as surgery.13 A study reported that an
age >70 years was associated with a significantly increased
risk from surgery for esophageal cancer.14 The stress-
buffering properties of physiological support following
esophagectomy were more evident in patients aged 70
years than in those aged <70 years. Thus, the age of 70
years was considered a critical cutoff point for identifying
patients who received esophagectomy as elderly. In the
current study, we retrospectively enrolled patients with
esophageal cancer and compared their surgical and long-
term survival outcomes by assigning them to two groups.
2. Methods
Patients who received curative esophagectomy for esoph-
ageal cancer between January 2001 and December 2012
were enrolled and assigned to two groups according to their
age at diagnosis: Group 1 comprised patients aged 70
years and Group 2 comprised patients aged <70 years.
Esophagectomy and reconstruction of the esophagus were
conducted using the Orringer transhiatal technique for
lower esophageal tumors and the two-stage IvoreLewis or
three-stage McKeown procedure for tumors of the mid and
upper third of the esophagus. Clinical data of the patients
were retrospectively collected and analyzed. The defini-
tions of tumors, metastatic descriptors, and stagingclassification used in the current study were based on the
definitions described in the seventh edition of the American
Joint Committee on Cancer staging manual.15 Thus, the
stages of patients who were treated before 2009 were
revised according to the new staging system. Because a
standard definition of celiac and cervical lymph nodes
related to lower thoracic and upper thoracic esophageal
cancer is not described in the manual, the stage of these
cases in both groups was considered as the M1 stage.
Preoperative evaluation included a detailed risk assess-
ment based on the history of cardiopulmonary, cerebro-
vascular, hepatic, and renal diseases. All patients were
subjected to endoscopy, barium esophagography, abdom-
inal sonography, computed tomography, cell and biochem-
istry profiling, electrocardiography, pulmonary functional
tests, and arterial blood-gas analysis before surgery. Pa-
tients with a clinical stage  Stage III and having a per-
formance status  2 were evaluated by a multidisciplinary
team and were considered surgical candidates. Following
esophagectomy of locally advanced or recurrent esopha-
geal cancer, eligible patients received concurrent or
sequential chemotherapy and/or radiotherapy, according
to their performance and tumor status. The adjuvant
chemotherapy involved first-line treatment using a
cisplatin-based doublet combination with fluorouracil and
advanced-line treatments (for 13 patients) with cetuximab
(for six patients), taxanes (for four patients), doxorubicin
(for two patients), and bevacizumab (for one patient).
Patients were regularly followed up for 1e2 months and
systemically examined every 3 months for the first 2 years,
and 6 months thereafter. The postoperative analysis
included chest roentgenography, computed tomography,
abdominal sonography, measurement of serum levels of
carcinoembryonal antigen (for adenocarcinoma) and squa-
mous cell carcinoma (for squamous cell carcinoma), and a
Tc-m99 whole body bone scan, and brain scan or whole
body positron emission tomography. Patients were imme-
diately examined if symptoms and signs specific to the
progression of a suspicious disease were observed. Tumor
progression or recurrence was defined using biopsy or at
least two positive clinical examinations.
Several variables, namely sex, nutritional status, per-
formance status, pulmonary function (functional vital ca-
pacity and first-second forced expiratory volume), tumor
location (upper third, middle third, and lower third), tumor
size, tumor grade (I, II, III, IV), histology, and chemo-
radiotherapy, were compared between the two groups to
determine the major effects of age on the surgical and
survival outcomes. The surgical outcomes were compared
using six variables, namely blood loss during surgery,
completeness of resection (R0: resection with negative
Table 2 Characteristics of patients according to treat-
ment group.
Characteristics Group A
70 y
(N Z 39)
Group B
<70 y
(N Z 146)
p
Sex, n (%)
Male 31 (79.5) 135 (92.5) 0.017
Female 8 (20.5) 11 (7.5)
Age (y), mean  SD 75.1  3.6 55.9  9.0 <0.001
ECOG performance status, n (%)
0 33 (84.6) 135 (92.5) 0.13
1 4 (10.3) 10 (6.8)
2 2 (5.1) 1 (0.7)
Nutrition status
Body mass index 16.0  2.4 15.8  2.7 > 0.99
Serum albumin 3.24  1.87 3.15  2.12 0.52
Pulmonary function tests, mean  SD
FVC (%) 75.5  5.6 77.8  4.8 <0.001
FEV1 (%) 71.2  4.5 76.8  3.2 <0.001
Comorbiditiesa, n (%) 15 (38.5) 52 (35.6) 0.15
Hypertensive
cardiovascular
disease
8 25
Diabetes 7 6
Liver cirrhosis 1 36
Uremia 0 5
Cerebrovascular
disease
1 1
Tumor size (cm),
mean  SD (range)
5.3  2.2
(0.7e12.0)
5.4  2.2
(0.5e12.5)
> 0.99
0e4.0 10 38
4.1e8.0 26 94
 8.1 3 14
TNM stage, n (%)
I 0 (0) 9 (6.2) 0.067
II 20 (51.3) 44 (30.1)
III 14 (35.9) 68 (46.6)
IV 5 (12.8) 25 (17.1)
Histologic
classification, n (%)
Adenocarcinoma 9 (23.1) 19 (13.0) 0.13
Squamous cell
carcinoma
30 (76.9) 127 (87.0)
Tumor location, n (%)
Surgery for elderly esophageal cancer 123margins; R1: resection with microscopic positive margins;
and R2: resection with grossly positive residual margins),
lengths of postoperative intensive care unit (ICU) and hos-
pital stays, morbidity, and mortality.
Patients who preoperatively received neoadjuvant
therapy were excluded. Survival was calculated as the
period from the date of surgery to the date of the most
recent follow-up or the date of death. Statistical analyses
were performed using the independent Student t test and
the Chi-square test or Fisher’s exact test for continuous and
categorical variables, respectively. Data were collected by
referring to medical records and by personally interviewing
the patients. The survival outcomes were calculated using
the KaplaneMeier method and compared using the log-rank
test. The analyses were performed using the SPSS/PCþ
Advanced Statistics software package (Version 12.0, SPSS
Inc., Chicago, Illinois, USA). Results were considered sta-
tistically significant when the p value was <0.05.
3. Results
Data on 895 patients diagnosed with and treated for
esophageal cancer were collected. The types of treatment
received by these patients are shown in Table 1. Of the
patients, 185 (20.7%) were enrolled in the current study.
Group 1 comprised of 39 patients and Group 2 comprised of
146 patients. Characteristics of these patients are shown in
Table 2. More than 95% of esophagectomies in both groups
were of the R0 resection type. Most patients (76.9%) with
pathologically advanced disease or tumor relapse had
received chemotherapy and/or radiotherapy. Compared
with the elderly patients in Group 1, a significantly higher
number of the younger patients in Group 2 had received
chemotherapy and/or radiotherapy.
The perioperative variables and surgical results of the
patients in both groups are shown in Table 3. Although
blood loss during surgery and the completeness of the
resection were comparable, the patients in Group 1 had
longer ICU and hospital stays compared with the patients in
Group 2. The patients in Group 1 showed higher rates of
morbidity and mortality following esophagectomy
compared with the patients in Group 2; although no sta-
tistical difference was observed. Among various comorbid-
ities, cardiopulmonary complications (30.8% and 6.8%)
affected the highest number of patients in both groups.
Three patients (7.7%) in Group 1 died following surgeryTable 1 Treatments by age group.
Groups/treatments Surgical
resection (%)*
Nonsurgical
treatment (%)*
Patients <70 y
(n Z 631)
188 (29.8%) 443 (70.2%)
Patients 70 y
(n Z 264)
48 (18.2%) 216 (81.8%)
Total (n Z 895) 236 (26.4%) 659 (73.6%)
Treatments include surgery alone, surgery plus adjuvant che-
moradiotherapy, and induction chemoradiotherapy plus sur-
gery, which was excluded in the study as described in the text.
*p < 0.001.
U/3 6 (15.4) 17 (11.6) 0.08
M/3 16 (41.0) 89 (61.0)
L/3 17 (43.6) 40 (27.4)
Adjuvant or salvage therapy, n (%)
With CRT 23 (59.0) 120 (82.2) 0.002
Without CRT 16 (41.0) 26 (17.8)
CRT Z chemoradiotherapy; ECOG Z Eastern Cooperative
Oncology Group; FEV1Z forced expiratory volume in 1 second;
FVCZ forced vital capacity; L/3Z lower third; M/3 Z middle
third; SD Z standard deviation; TNM Z tumor, node, metas-
tases; U/3 Z upper third.
a Multiple complex comorbidities were observed in several
patients.
Table 3 Treatment results of patients with esophageal
cancer.
Results/groups Elderly
(N Z 39)
Nonelderly
(N Z 146)
p
Blood loss (mL), mean  SD 258  98.7 270  140.5 0.99
Completeness of resection, n (%)
R0 37 (95) 140 (96)
R1 2 (5) 5 (3) 0.72
R2 0 1 (1)
ICU stay (d), mean  SD 4.5  2.8 3.1  1.6 0.001
Post-OP stay (d),
mean  SD (range)
30.2  16.4
(12e252)
21.6  8.8
(10e41)
0.02
Mortality, n (%) 3 (7.7) 5 (3.4) 0.37
Morbiditiesa, n (%) 18 (46.1) 43 (29.5) 0.07
Cardiopulmonary 12 (30.8) 10 (6.8)
Arrythmia 3 1
Respiratory failure 2 6
Pneumonia 10 3
ARDS 2 3
AMI 1 0
Heart failure 1 0
GI bleeding 1 4
Pleural effusion 2 7
Sepsis 4 1
Anastomotic leak 4 8
Wound infection 3 7
Reoperation 3 0
Graft necrosis 1 0
Postoperative bleeding 1 0
Tracheostomy 1 0
Laryngeal nerve palsy 2 6
Chylothorax 1 3
AMI Z acute myocardial infarction; ARDS Z acute respiratory
distress syndrome; GI Z gastrointestinal; ICU Z intensive care
unit; NS Z no significance; Post-OP Z postoperative; SD Z
standard deviation.
a Multiple complex complications were observed in several
patients.
124 H.-C. Liu et al.because of heart failure (one patient) and pneumonia with
adult respiratory distress (two patients). By contrast, five
deaths (3.4%) occurred in Group 2 because of postoperative
pneumonia with adult respiratory distress syndrome (three
patients) and anastomotic leakage with sepsis (two pa-
tients, one receiving intrathoracic anastomosis and one
receiving intra-abdominal anastomosis).
The mean follow-up period of all patients was 20.8
months (range, 0.5e129.9 months). The long-term survival
outcomes of patients with tumors of different grades are
shown in Figure 1. The tumor grade significantly influenced
the survival outcomes. Figure 2 shows the overall survival
outcomes of patients in both groups. With less intensive
chemotherapy and/or radiotherapy, the patients in Group 1
[median survival time (MST)Z 15.8 months; 95% confidence
interval (CI) Z 7.3e24.3 months] had longer survival
compared with the patients in Group 2 (MST Z 13.7
months; 95% CI Z 12.1e15.3 months); however, the dif-
ference was not statistically significant (p Z 0.44). No pa-
tient who received chemotherapy and/or radiotherapy
following esophagectomy showed significantly longersurvival than that of patients who received esophagectomy
alone (p Z 0.19 and 0.08).4. Discussion
The most effective treatment for primary esophageal can-
cer is curative esophagectomy.8,16 However, esoph-
agectomy is reported to have high morbidity and mortality.8
Physicians, caregivers, and elderly patients must consider
esophagectomy, because age can offset oncologic advan-
tages.5,10 In the current study, age significantly influenced
the rate of surgical resection. Compared with the patients
in Group 2 (29.8%), a lower number of patients in Group 1
(18.2%) received surgical resection. By contrast, the elderly
patients who received less intensive chemotherapy and/or
radiotherapy following surgery showed longer survival
compared with the younger patients; although no signifi-
cant difference was observed. Several factors besides
esophagectomy are likely to have influenced this result and
require further discussion and evaluation in elderly
patients.
In the current study, preoperative pulmonary functions
in the elderly patients were significantly poorer than those
in the younger patients. The poor physiological conditions
adversely affected the postoperative outcomes: rates of
mortality and morbidity were higher in the elderly patients
than in the younger patients (Table 3). Elderly patients
typically have limited functional reserve and a poor per-
formance status.13,17 Esophagectomy and anesthesia affect
elderly patients, prolonging the period for recovery and
hospital stay. Old age delays recovery from functional loss
of physiological stress loads.5,7,9,14 However, in the current
study, the compared data did not differ significantly,
probably because of advanced perioperative care tech-
niques and surgical technologies. Functional changes
caused by aging adversely affect recovery following
esophagectomy in elderly patients, particularly by pro-
longing the postoperative ICU and hospital stay.
In the current study, longer survival was observed in the
elderly patients than in younger patients, with no statistical
significance. The association between esophagectomy and
the survival outcome in elderly patients has been contro-
versial.5,8,9 Differences in inclusion criteria, the lack of a
standard definition of an elderly age, and variation in study
designs may have caused variable discrepancies.5 From the
viewpoint of treatment, the advantages of esophagectomy
with lymph node dissection depend upon accurate tumor
grading, which provides data valuable in determining
whether adjuvant therapy is necessary.9 Moreover, surgery
can resolve functional obstruction by a tumor, potentially
preventing tumor-related complications and improving
quality of life and nutritional support. Thus, the role of
esophagectomy cannot be evaluated according to the result
of survival outcomes. In the current study, patients with
preoperative neoadjuvant therapy were excluded to avoid
confounding factors attributable to unclear staging, which
may crucially affect the outcome of surgery.1,15 Thus, the
results of the current study are likely to accurately reflect
the effects of age on the outcomes of esophagectomy.
Cancer is an immunogenic disease, and the immune
system protects the body against tumorigenesis.18 The
Patients at risk: 
Stage I + II 73 40 21 9 4 1 0 
Stage III 82 13 3 2 2 2 2 
Stage IV 30  3 0 0 0 0 0 
Median survival time 95% CI 
(months) 
___ Stage I+II (39.5%) 36.4   25.5-47.3 
----- Stage III (44.3%) 10.8   9.1-12.5
…... Stage IV (16.2%)  8.3   6.3-10.3 
Hazard ratio     2.14 
P value     < 0.001
Figure 1 Survival outcomes in patients with esophageal cancer according to cancer stage without consideration of age.
CI Z confidence interval.
Surgery for elderly esophageal cancer 125elderly population, with decreased immune function, has
an increased risk of cancer, but age may change tumor
behavior. In the current study, elderly patients who
received less intensive chemotherapy and radiotherapy
following esophagectomy showed a longer survival time
(MST Z 15.8 months) compared with the younger patients
(MST Z 13.7 months). Such a survival benefit in elderly
patients seems to contradict the effects of a poor immune
system in old age. This result supports the suggestion of
Weksler et al19 that aging slows tumor growth, reduces
metastasis, and increases survival. Age has diverse effects
on both tumor growth and tissue aging.20 Cellular senes-
cence seems to activate a potent mechanism of tumor
suppression and protection,21 resulting in slow growth of
cancer in elderly patients. However, various factors,
including exposure to carcinogens and changes in the host
defense during aging, may affect the outcomes of treat-
ment for esophageal cancer. The current study could not
determine the complex association between cancer and
aging, but the effect of age on the treatment of elderly
patients with esophageal cancer should not be neglected.
Additional studies are necessary to understand the rela-
tionship between carcinogenesis and aging in detail.
Considering the efficacy and benefits of esophagectomy
in the elderly patients, the procedure must be used in
combination with alternative nonsurgical treatments, such
as chemotherapy and radiotherapy. Several studies have
shown that in an advanced stage of cancer or a tumorrelapse, when adjuvant or salvage therapy is used as a
treatment option, elderly patients show a greater response
to less intensive chemotherapy and/or radiotherapy than
younger patients do.5,22 Reluctance to treat elderly pa-
tients and fear of toxicity are likely causes of the small
number of elderly patients who receive chemotherapy and/
or radiotherapy.13 Moreover, several randomized trials have
shown no benefits of chemoradiotherapy.23,24 Furthermore,
previous studies based on target therapy for esophageal
cancer could not prove that it benefits treatment-related
survival.25,26 Thus, considering these unsatisfactory re-
sults, esophagectomy alone yields more benefits in elderly
patients than in younger patients.
Finally, elderly patients are likely to die from various
age-related diseases, such as cardiopulmonary disorders.
Additional studies are required to determine whether the
superior overall survival outcomes with no statistical sig-
nificance support the benefit of esophagectomy in elderly
patients with esophageal cancer. A previous report by Yang
et al5 suggested that only a few patients with esophageal
cancer died from conditions other than cancer. Thus, con-
ditions other than cancer should have a limited effect on
the survival analysis of elderly patients with esophageal
cancer.
This study has limitations such as a retrospective design,
mixed therapies, and mismatched comparisons between
the two groups. However, the survival benefit of esoph-
agectomy in elderly patients with esophageal cancer
Patients at risk: 
Elderly 39 13 5 0 0 0 0 
Non-elderly 146 42 19 12 6 3 2 
Median survival time 95% CI 
(months) 
___ Elderly (21.1%)  15.8   7.3-24.3 
….. Nonelderly (78.9%) 13.7   12.1-15.3 
Hazard ratio     1.14
P value     0.44
Figure 2 Survival outcomes in patients with esophageal cancer following esophagectomy according to age at diagnosis.
CI Z confidence interval.
126 H.-C. Liu et al.cannot be denied, because the surgical procedure is the
main evidence-based effective treatment for esophageal
cancer and has positive long-term survival outcomes.1 In
addition; frequency-matching between the two groups with
different ages in an age-based study is difficult. If surgery is
an appropriate treatment modality, elderly patients should
not be denied this option because of their age.
The results of the current study suggest that esoph-
agectomy followed by less intensive chemotherapy and/or
radiotherapy in elderly patients has a superior survival
outcome compared with that in younger patients; although
perioperative courses in elderly patients may be more
complicated. Considering that surgery remains the most
effective modality for treating solid tumors, age alone
should not affect treatment-related decisions and should
not be included in exclusion criteria. In elderly patients
with esophageal cancer, esophagectomy yields a superior
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